DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Adenoscan (Adenosine) - Summary

 
 



ADENOSCAN SUMMARY

Adenosine is an endogenous nucleoside occurring in all cells of the body.

Intravenous Adenoscan is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately (See WARNINGS).

 


See all Adenoscan indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Adenoscan (Adenosine)

The effect of PDRN, an adenosine receptor A2A agonist, on the healing of chronic diabetic foot ulcers: results of a clinical trial. [2014]
ulcer healing in patients with diabetes... CONCLUSIONS: PDRN facilitates the healing of Wagner 1 or 2 diabetic foot ulcers.

Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. [2013]
treating hypercholesterolemia and other cardiometabolic risk factors... CONCLUSIONS: ETC-1002 significantly lowered LDL-C levels up to 27% across a broad

The new oral adenosine A1 receptor agonist capadenoson in male patients with stable angina. [2012]
capadenoson in patients with stable angina... CONCLUSIONS: In patients with stable angina capadenoson lowers exercise HR at

Treatment of Unexplained Syncope: A Multicenter, Randomized Trial of Cardiac Pacing Guided by Adenosine 5'-triphosphate Testing. [2011.11.15]
CONCLUSIONS: This study suggests that, in elderly patients with SUO and positive ATP tests, active dual-chamber pacing reduces syncope recurrence risk by 75% (95% CI 44% to 88%). CLINICAL TRIAL REGISTRATION INFORMATION: http://www.controlled-trials.com/ISRCTN00029383; Unique Identifier: ISRCTN00029383.

Adenosine A2(A) receptor gene polymorphism (1976C>T) affects coronary flow reserve response during vasodilator stress testing in patients with non ischemic-dilated cardiomyopathy. [2011.08]
OBJECTIVES: Patients with non ischemic-dilated cardiomyopathy (DCM) are characterized by an activation of the adenosinergic system and reduced coronary flow reserve (CFR) evaluated by transthoracic Doppler echocardiography during vasodilator adenosinergic stress (dipyridamole administration). The aim of this study was to assess whether genetic polymorphisms (263C>T and 1976C>T) of the A2(A) receptor gene affect CFR response in patients with DCM... CONCLUSION: These data demonstrate that A2(A) 1976C>T polymorphism is associated with a blunted coronary vasodilatory response in patients with DCM, and support a direct consequences of this single nucleotide polymorphism for protein expression. Additional studies are needed to better define the functional role of this genetic variant as well as to clarify the potential clinical impact of genetics during pharmacological stress cardiac imaging.

more studies >>

Clinical Trials Related to Adenoscan (Adenosine)

ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI) [Completed]
Adenoscan® (adenosine) is an approved pharmacological stress agent indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. The investigational drug, regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist, the receptor responsible for coronary vasodilation, and is being studied for potential use as a pharmacologic stress agent in myocardial perfusion imaging (MPI) studies. This study will compare the safety and efficacy of regadenoson to that of Adenoscan in detecting reversible myocardial perfusion defects.

ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI) [Completed]
Adenoscan® (adenosine) is an approved pharmacological stress agent indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. The investigational drug, regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist, the receptor responsible for coronary vasodilation, and is being studied for potential use as a pharmacologic stress agent in myocardial perfusion imaging (MPI) studies. This study will compare the safety and efficacy of regadenoson to that of Adenoscan in detecting reversible myocardial perfusion defects.

Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve (FFR) [Recruiting]

Myocardial Protection With Adenosine Preconditioning [Completed]
Adenosine has been proved to be an important mediator of myocardial protection induced by ischemic preconditioning. The hypothesis of this study is that adenosine preconditioning can provide additional myocardial protection in the setting of pediatric open heart surgery with cardioplegia and cardiopulmonary bypass.

Effect of Ticagrelor vs. Dipyridamole on Adenosine Uptake [Active, not recruiting]
The investigators are trying to determine if a single dose of Ticagrelor will increase delivery of intraarterially-infused adenosine into the forearm interstitium, consistent with adenosine reuptake blockade.

more trials >>

Reports of Suspected Adenoscan (Adenosine) Side Effects

Coronary Artery Disease (8)Hypertension (3)Anaemia Postoperative (2)Diabetes Mellitus Inadequate Control (2)Supraventricular Tachycardia (2)Hyperlipidaemia (2)Ventricular Tachycardia (2)Ischaemic Cardiomyopathy (1)Angina Unstable (1)Haemodynamic Instability (1)more >>


Page last updated: 2014-11-30

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015